Australia Recombinant Protein Therapeutics Cdmo Market Size & Outlook
Related Markets
Australia recombinant protein therapeutics cdmo market highlights
- The Australia recombinant protein therapeutics cdmo market generated a revenue of USD 616.3 million in 2023 and is expected to reach USD 1,548.1 million by 2030.
- The Australia market is expected to grow at a CAGR of 14.1% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 616.3 million |
| Market revenue in 2030 | USD 1,548.1 million |
| Growth rate | 14.1% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, Australia accounted for 3.0% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,968.6 million by 2030.
Interferons was the largest segment with a revenue share of 21.43% in 2023. Horizon Databook has segmented the Australia recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
Australia’s recombinant protein therapeutics CDMO market is anticipated to grow gradually over the forecast period due to superior clinical research and healthcare infrastructure, as well as skilled research capabilities. Moreover, the government is supporting and improving the clinical trial environment, as evidenced by substantial investments.
Such actions are likely to promote advanced therapeutic discovery activities in the country, thus promoting the market in Australia. Moreover, therapeutics discovery services in the country are relatively cost-effective compared to developed economies, such as the U.S. This is further expected to promote growth of Australia recombinant protein therapeutics CDMO market.
The University of Queensland, in collaboration with the University of Technology Sydney and CSIRO, formed The National Biologics Facility in the country. This facility has expertise in phage display, molecular biology, antibody discovery & engineering, recombinant protein production, mammalian cell culture, & biopharmaceutical development and offers custom manufacturing solutions for biological therapeutics. This collaboration is expected to enhance the potential of developing and manufacturing recombinant proteins in Australia.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Enzene Biosciences | View profile | 251-500 | Pune, Maharashtra, India, Asia | http://www.enzene.com/ |
| Biovian | View profile | 101-250 | Turku, Western Finland, Finland, Europe | http://www.biovian.com |
| HALIX | View profile | 11-50 | Leiden, Zuid-Holland, The Netherlands, Europe | https://www.halix.nl |
| Richter-Helm | View profile | 251-500 | Hamburg, Hamburg, Germany, Europe | http://www.richter-helm.eu |
| Batavia Biosciences | View profile | 101-250 | Leiden, Zuid-Holland, The Netherlands, Europe | http://www.bataviabiosciences.com/ |
| Curia | View profile | 1001-5000 | Albany, New York, United States, North America | https://curiaglobal.com |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| WuXi Biologics (Cayman) Inc | View profile | 12740 | No. 108, Meiliang Road, Mashan Binhu District, Wuxi, China, People's Republic of, 214092 | https://www.wuxibiologics.com |
| FUJIFILM Holdings Corp | View profile | 83784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | http://www.fujifilmholdings.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
Australia recombinant protein therapeutics cdmo market size, by source, 2018-2030 (US$M)
Australia Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
